Reminder – Melanoma Consumer Breakfast this Saturday 6th October 2108

Sat 6th October 2018, 8:00-9:30am All members of the melanoma community are invited to attend a Melanoma Consumer Breakfast. The Breakfast is part of the Australasian Melanoma Conference – which also has great consumer forums. The program is on the website. All bookings can be made via the conference website

Melanoma survivors march to honour lost friends and raise awareness

Melanoma has a reputation for being one of the most curable types of cancers, but that does not mean much to survivors such as Jay Allen and Aaron Kelly.

Free skin checks for South West community

The Bunbury Skin Cancer Clinic is partnering with melanomaWA to provide the community with free skin checks on February 24.

Townsville’s First Ever Twilight Melanoma March

She will next month join Townsville’s first ever twilight Melanoma March in honour of her mother, Gina Sellen, who lost her battle against the deadly cancer in 2016.

Cancer in the News

Feature Articles

SUU students pilot Eyes on Cancer skin cancer project

With Utah suffering the highest melanoma rate in the United States, Southern Utah University students are now helping rally a first line of defense: hairdressers who regularly look at people’s scalps, where the deadliest melanomas often form.


Posted in Melanoma News, Patients, Latest News

Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in Melanoma

Ryan J. Sullivan, MD, associate director of Melanoma at the Massachusetts General Hospital, discusses the significance of the BRAF/MEK combination dabrafenib (Tafinlar) and trametinib (Mekinist), which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.


Posted in Melanoma News, Health Professionals, Video Reports

CR With Dabrafenib/Trametinib Linked to Long-Term Survival in BRAF+ Melanoma

Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response (CR) to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years, according to a pooled analysis of data from the phase III COMBI-d and COMBI-v studies.1


Posted in Melanoma News, Health Professionals, Of Interest

Melanoma Education is Key to Saving Lives

The incidence of melanoma has increased to the head and neck by more than 50% in children, adolescents and young adults over the past nearly 20 years.


Posted in Melanoma News, Health Professionals, Of Interest

2019 Events

Calculate your risk of getting melanoma Sunscreen calculator
Map of body for recording areas of skin causing you concern on your body Target Therapy Finder